ETFIQData as of Nov 18, 2026. · etfiq.com/funds/pjp

PJP Fact Sheet: Invesco Pharmaceuticals ETF

Share
$128.23
close, Nov 18, 2026

Over the year to Nov 18, 2026, PJP returned +24.4% in total and charged 0.58% a year.

1-year total return
+24.4%
to Nov 18, 2026
Expense ratio
0.58%
a year
Net assets
$602m
on Nov 17, 2026
Net flow, last 5 trading days
+$5.2m
daily basis to Nov 17, 2026

Growth of $10,000, 1 year

PJP $12,439 +24.4% · IVV $11,186 +11.9% · Total return, distributions reinvested, Nov 18, 2025 to Nov 18, 2026.

Returns

WindowTotal return
1 month+3.8%
3 months−2.4%
Year to date+23.6%
1 year+24.4%
3 years+89.2%
5 years+68.0%

Total return, distributions reinvested, each window to Nov 18, 2026.

Ten largest positions

HoldingWeight
Eli Lilly & Co6.18%
Gilead Sciences Inc6.16%
AbbVie Inc5.93%
Amgen Inc5.56%
Johnson & Johnson5.49%
Pfizer Inc5.44%
Merck & Co Inc4.93%
Abbott Laboratories4.84%
Viatris Inc3.75%
Amneal Pharmaceuticals Inc3.61%

PJP top ten by weight, 51.9% of the fund, of its 31 equity positions, from the holdings published by its issuer for Nov 17, 2026.

Facts

Equity fund · Tracks the Dynamic Pharmaceutical Intellidex Index · First traded Jun 23, 2005 · Benchmark Its own holdings, as of Nov 17, 2026

Source: ETFIQ, from issuer disclosures, SEC filings and exchange prices. Returns from daily closes, distributions reinvested; each number is dated beside it, and every one is on the fund’s page.Cite as: ETFIQ, PJP Fact Sheet: Invesco Pharmaceuticals ETF. Data as of Nov 18, 2026. https://etfiq.com/funds/pjp/fact-sheet/ETFIQ is an independent publisher. Not an issuer, broker or adviser. No recommendations. Printed from etfiq.com/funds/pjp.